Journal article
Tocolytics for suspected intrapartum fetal distress.
- Kulier R Departement de Gynecologie et d'Obstetrique, Hopitaux Universitaires de Geneve, Boulevard de la Cluse 32, Geneve 14, Switzerland, 1211. rkulier@hotmail.com
- Hofmeyr GJ
- 2000-05-05
Published in:
- The Cochrane database of systematic reviews. - 2000
Female
Fetal Distress
Hexoprenaline
Humans
Magnesium Sulfate
Obstetric Labor Complications
Pregnancy
Terbutaline
Tocolytic Agents
English
BACKGROUND
Prophylactic tocolysis with betamimetics and other agents has become widespread as a treatment for fetal distress. Uterine relaxation may improve placental blood flow and therefore fetal oxygenation. However there may also be adverse maternal cardiovascular effects.
OBJECTIVES
The objective of this review was to assess the effects of tocolytic therapy for suspected fetal distress on fetal, maternal and perinatal outcomes.
SEARCH STRATEGY
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of last search: February 1999.
SELECTION CRITERIA
Randomised trials comparing tocolytic therapy with no treatment or treatment with another tocolytic agent for suspected fetal distress.
DATA COLLECTION AND ANALYSIS
Two reviewers assessed trial quality and extracted data.
MAIN RESULTS
Three studies were included. Compared with no treatment, there were fewer failed improvements in fetal heart rate abnormalities with tocolytic therapy (relative risk 0.26, 95% 0.13 to 0.53). Betamimetic therapy compared with magnesium sulphate showed a non-significant trend towards reduced uterine activity (relative risk 0.07, 95% confidence interval 0.00 to 1.10).
REVIEWER'S CONCLUSIONS
Betamimetic therapy appears to be able to reduce the number of fetal heart rate abnormalities and perhaps reduce uterine activity. However there is not enough evidence based on clinically important outcomes to evaluate the use of betamimetics for suspected fetal distress.
Prophylactic tocolysis with betamimetics and other agents has become widespread as a treatment for fetal distress. Uterine relaxation may improve placental blood flow and therefore fetal oxygenation. However there may also be adverse maternal cardiovascular effects.
OBJECTIVES
The objective of this review was to assess the effects of tocolytic therapy for suspected fetal distress on fetal, maternal and perinatal outcomes.
SEARCH STRATEGY
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of last search: February 1999.
SELECTION CRITERIA
Randomised trials comparing tocolytic therapy with no treatment or treatment with another tocolytic agent for suspected fetal distress.
DATA COLLECTION AND ANALYSIS
Two reviewers assessed trial quality and extracted data.
MAIN RESULTS
Three studies were included. Compared with no treatment, there were fewer failed improvements in fetal heart rate abnormalities with tocolytic therapy (relative risk 0.26, 95% 0.13 to 0.53). Betamimetic therapy compared with magnesium sulphate showed a non-significant trend towards reduced uterine activity (relative risk 0.07, 95% confidence interval 0.00 to 1.10).
REVIEWER'S CONCLUSIONS
Betamimetic therapy appears to be able to reduce the number of fetal heart rate abnormalities and perhaps reduce uterine activity. However there is not enough evidence based on clinically important outcomes to evaluate the use of betamimetics for suspected fetal distress.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1002/14651858.CD000035
- PMID 10796094
- Persistent URL
- https://folia.unifr.ch/global/documents/33145
Statistics
Document views: 23
File downloads: